Alector does not pay a dividend yield to its shareholders, maintaining a policy typical of early-stage and clinical-stage biotechnology firms. Because pre-revenue biopharmaceutical enterprises must channel all incoming capital reserves, collaboration payments, and public offering proceeds directly into costly research and development pipelines, clinical trials, and laboratory operations, they do not distribute cash returns. Consequently, the dividend yield remains zero, as investors purchase shares strictly for long-term capital appreciation.